🚨 #ESMO26 Lung Cancer: Top Ten by @OncoAlert 🫁 The abstracts our faculty picked as must-know from Madrid 👇 1️⃣ DeLLphi-305 (LBA3): tarlatamab + durvalumab, 1L maintenance in ES-SCLC 2️⃣ Krascendo 1 (LBA5): divarasib vs sotorasib/adagrasib in KRAS G12C NSCLC 3️⃣ SAFFRON (LBA6): osimertinib + savolitinib in EGFRm MET+ NSCLC post-osimertinib 4️⃣ OptiTROP-Lung04 (LBA67): final OS, sac-TMT vs chemo after EGFR-TKI 5️⃣ OptiTROP-Lung06 (LBA66): sac-TMT + pembro, 1L PD-L1-negative non-squamous NSCLC 6️⃣ PERSEE (2614O): pembro ± chemo, 1L PD-L1 ≥50% 7️⃣ SANOVO (LBA69): savolitinib + osimertinib, 1L EGFRm MET-overexpressed NSCLC 8️⃣ IFCT-2103 DIAL (2618RO): continue pembro vs observation at 6 months 9️⃣ PANKU-Lung01 (LBA71): iza-bren after third-generation EGFR TKI 🔟 SARON (2613O): consolidation radiotherapy in oligometastatic NSCLC #lcsm #OncoAlert #MedTwitter Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @LeciaSequist @bensolomon1 @VanitaNoronha +@alexdrilon @JordiRemon @caliraf @JulienMazieres @TerriConneran
ESMO 2026
2026 年 10 月 23–27 日 · Madrid · 共 2840 条
#LCSM
★★★10 人 · 26 条
本事件热度走势
当前热度 4·可比范围峰值 4（10月24日 18:00）·近 24 小时可比范围变化 –·当前参与者 6
先划清证据边界：本次提供的背景文献均不涉及肿瘤领域，其中的缩写LCSM分别指激光共聚焦扫描显微镜[1][2][3][4]与潜在变化得分模型[5][6]，与肺癌社群标签#LCSM只是缩写巧合。因此，帖中所涉肺癌ADC及TOP1 payload这一类别“站住脚”的已发表III期证据，在给定材料中找不到对应文献，具体试验与数据待确认，本文也不就类别成熟度作超出材料的判断。
会议信息要点如下：ESMO26于10月23–27日在马德里举行，现场帖集中在会前与开幕当日。@ADesaiMD按排名列出其前七项胸部肿瘤看点，并明确其中5项III期已公布阳性topline，而ESMO是“终于能看到效应量”的场合，每项试验各自回答的问题将在此揭晓；这七项试验的名称与任何疗效数字均未披露。@GlopesMd另行盘点前十场LCSM报告，@OncLive则发起并公布了读者最期待肺癌摘要的投票结果。与“等效应量”并行还有第二条讨论线：@MeDucationai转述@lungoncdoc提出的机制问题——若耐药存在于TOP1 payload，换一个抗体靶点未必能挽回疗效，而当前多数在研肺癌ADC恰恰携带TOP1 payload。
相对已有认识，本次会议可能推进两步：其一，把已公布的阳性topline从二元结论细化为可比较的效应量，并明确每项III期各自回答的临床问题；其二，把ADC讨论的焦点从“换抗体靶点”前移到“耐药究竟位于payload还是抗体”，为即将公布的读数预设解读框架。由于背景材料不含同类ADC关键试验数据，这一步只能就帖内信息描述，与既有III期的正式对照待确认。
局限在于：发帖时会议尚未开幕或刚刚开幕，关键试验名称、人群与主要终点数值一概未披露，社交平台观点属会前预期而非同行评议数据；两条讨论线最终分量如何，取决于ESMO26正式报告的效应量与ADC数据。
- 1.Ecotoxicity and genotoxicity of polystyrene microplastics on higher plant Vicia faba · Environ Pollut 2019
- 2.Impact of polystyrene nanoplastics (PSNPs) on seed germination and seedling growth of wheat (Triticum aestivum L.) · J Hazard Mater 2020
- 3.The Semen pH Affects Sperm Motility and Capacitation · PLoS One 2015
- 4.Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning · J Biomed Mater Res A 2008
- 5.Teacher's Corner: Latent Curve Models and Latent Change Score Models Estimated in R · Struct Equ Modeling 2012
- 6.White matter and memory in healthy adults: Coupled changes over two years · Neuroimage 2016
gilberto lopes@GlopesMd 引用@Hidehito HORINOUCHI@HHorinouchi Víctor Albarrán-Artahona@vmalbarran Hidehito HORINOUCHI@HHorinouchi Hidehito HORINOUCHI@HHorinouchi Hidehito HORINOUCHI@HHorinouchi Hidehito HORINOUCHI@HHorinouchi Dr. Antonio Calles 🫁🚭@Tony_Calles 🧬 @LeXiuning 全面探讨了 ctDNA 动态变化以及 EGFRmut 肺癌患者的适应性强化治疗方案。 核心结论：联合治疗方案是一线治疗的默认选择。 #ESMO26 #LCSM
Hidehito HORINOUCHI@HHorinouchi 引用@Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1
VJ Oncology@VJOncology Prof Tom John@TommyJohn00 Hidehito HORINOUCHI@HHorinouchi Lung Cancers Today@Lung_Cancers Hidehito HORINOUCHI@HHorinouchi Lung Cancers Today@Lung_Cancers OncLive.com@OncLive 您最期待在 2026 年 ESMO 大会上看到哪篇肺癌摘要？ @myESMO #ESMO2026 #lcsm #oncology
LUNGevity Foundation@LUNGevity Dr. Antonio Calles 🫁🚭@Tony_Calles 你真当之无愧！❤️ #ESMO26 有你在，#LCSM 社群好多了！！！继续加油，朋友！！💪
引用@It was an amazing surprise! Gracias Totales! #ESMO26
OncLive.com@OncLive VJ Oncology@VJOncology Tom Newsom-Davis@tnewsomdavis VJ Oncology@VJOncology Hidehito HORINOUCHI@HHorinouchi 引用@Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1
Hidehito HORINOUCHI@HHorinouchi 引用@Delighted to join Dr Yi-Chen Zhang, Dr Calvo de Juan and Prof Yi-Long Wu in discussing the role of local therapy in non-small cell lung cancer at #ESMO26 in #Madrid this afternoon. Superb case discussion and fascinating insights into novel approaches such as the role of ctDNA In selection and monitoring of patients. @myESMO @CancerInstIRE @tcddublin @TrinityMed1
Prof Tom John@TommyJohn00 Prof Tom John@TommyJohn00 PACE lung：ctDNA 未清除者的治疗升级。希望能进一步了解 ctDNA 阳性组的共突变情况。#LCSM #ESMO26
Lung Cancers Today@Lung_Cancers MeDucation@MeDucationai 引用@Important implications for lung cancer, too. We’re behind breast cancer in understanding optimal ADC sequencing, but emerging data raise an important concern: switching targets may not overcome resistance when the payload remains the same... #ESMO26